Clinical and demographic characteristics of the samples and subjects included in the study.

*At least two-years of follow-up with the same disease modifying therapy (DMT) from a base line visit (serum sample extracted before starting the DMT) to a 24 months visit.
**EDSS: Expanded Disability Status Scale. MSSS: Multiple Sclerosis Severity Score.
***It was included: adverse events, pregnancy, drug withdrawal for lack of efficacy, and patient decision.